Protective type I interferon responses in mycobacterial infection

# 1 Title

- 2 Type I interferon responses contribute to immune protection against mycobacterial infection
- 3 Authors
- 4 Andrea Szydlo-Shein<sup>1</sup>, Blanca Sanz-Magallón Duque de Estrada<sup>1</sup>, Joshua Rosenheim<sup>1</sup>, Carolin T.
- 5 Turner<sup>1</sup>, Evdokia Tsaliki<sup>1</sup>, Marc C. I. Lipman<sup>2,3</sup>, Heinke Kunst<sup>4,5</sup>, Gabriele Pollara<sup>1</sup>, Philip M. Elks<sup>6</sup>,
- 6 Jean-Pierre Levraud<sup>7</sup>, Elspeth M. Payne<sup>8</sup>, Mahdad Noursadeghi<sup>1</sup>, Gillian S. Tomlinson<sup>1\*</sup>

# 7 Affiliations

- 8 <sup>1</sup>Division of Infection and Immunity, University College London, London, UK
- 9 <sup>2</sup>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK
- 10 <sup>3</sup>UCL Respiratory, University College London, London, UK
- 11 <sup>4</sup>Barts Health NHS Trust, London, UK
- 12 <sup>5</sup>Blizard Institute, Queen Mary University of London, London, UK
- <sup>6</sup>The Bateson Centre, School of Medicine and Population Health, The University of Sheffield,
   Sheffield, UK
- <sup>7</sup>Université Paris-Saclay, CNRS UMR9197, Institut Pasteur, Université Paris-Cité, Institut des
   Neurosciences Paris-Saclay, 91400 Saclay, France
- 17 <sup>8</sup>Research Department of Haematology, Cancer Institute, University College London, London, UK
- 18 \*Corresponding author
- 19 Corresponding author
- 20 Gillian S. Tomlinson, Email: g.tomlinson@ucl.ac.uk

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Protective type I interferon responses in mycobacterial infection

#### 22 ABSTRACT

23 Reasons for the spectrum of severity of active tuberculosis (TB) disease are incompletely 24 understood. We sought to identify master regulators of host immune responses that determine 25 disease severity in pulmonary TB. We performed molecular profiling of human in vivo immune 26 responses to discover associations with the extent of radiographic TB disease in a patient cohort. 27 We then undertook mechanistic studies to test causality for the observed associations using the 28 zebrafish larval Mycobacterium marinum infection model. Transcriptional profiling of human immune 29 recall responses to tuberculin skin test (TST) challenge, a surrogate for immune responses to TB in 30 the lung, revealed that type I interferon activity in the TST transcriptome was inversely associated 31 with radiological disease severity. Abrogation of type I interferon signalling, achieved by CRISPR-32 mediated mutagenesis of stat2, led to increased susceptibility of zebrafish larvae to M. marinum 33 infection, as a result of reduced recruitment of myeloid cells required to restrict mycobacterial growth, 34 to the site of disease. Our data support a host protective role for type I interferon responses in 35 mycobacterial infection, with potential applications for risk-stratification of adverse outcomes and development of a host-directed therapy to mitigate against severe disease. 36

#### 37 ONE SENTENCE SUMMARY

38 Type I interferon responses contribute to host immune protection in mycobacterial infection by 39 recruitment of myeloid cells to the site of disease.

Protective type I interferon responses in mycobacterial infection

#### 41 INTRODUCTION

42 Mycobacterium tuberculosis (Mtb) infection results in diverse clinical manifestations, ranging from 43 asymptomatic infection to active tuberculosis (TB), which comprises an enormous spectrum of 44 disease severity (1, 2). Although we know that immune responses contribute to the risk of disease, 45 current understanding of the role of immune response variation in disease severity is limited. 46 Identification of immune correlates of disease severity may offer new insights into the immune 47 pathways that contribute to protection and pathogenesis. This is necessary to enable novel vaccine 48 design and evaluation, stratify disease risk in people who become infected and inform development 49 of novel host-directed therapies to shorten treatment regimens, mitigate against antimicrobial 50 resistance, and against the chronic sequelae of tissue injury in TB (3).

51 Variation in tissue immunology of human TB at the site of established disease is likely confounded 52 by differences in the chronicity of the disease process. To overcome this limitation, we evaluated in vivo immune responses at the site of a standardised antigenic challenge using the tuberculin skin 53 54 test (TST). We have previously shown that transcriptional profiling of skin biopsies from the site of 55 the TST provides comprehensive molecular and systems level evaluation of human in vivo immune 56 responses to Mtb with significantly greater sensitivity than conventional clinical and histological 57 assessments (4, 5). The TST gene signature is enriched within pulmonary TB granulomas and 58 accounts for genome-wide differences in the transcriptomes of TB infected lung compared to healthy 59 lung tissue (5, 6). Therefore, the TST provides a faithful and readily accessible surrogate to study 60 immune responses at the site of TB disease.

61 In the present study, we identified quantitative variation in immune pathways in the TST response 62 correlated with the severity of human TB disease, and then tested the hypothesis that these 63 pathways were causally related to outcomes of *Mycobacterium marinum* infection in zebrafish larvae. 64 This natural host-pathogen interaction generates granulomatous inflammation that recapitulates key 65 aspects of human TB pathology and in particular, provides unparalleled opportunities to study innate 66 immune responses in isolation, given the absence of functional adaptive immunity until 3-4 weeks 67 (7). Our innovative strategy revealed an inverse relationship between type I interferon activity and 68 radiographic severity of human TB, suggesting a host-protective role for type I interferons, that we 69 confirmed in zebrafish larvae by showing that mutagenesis of stat2 to model abrogation of 70 downstream type I interferon signalling led to increased severity of *M. marinum* infection.

# 71 **RESULTS**

# 72 Outlier analysis of the TST transcriptome defines human in vivo immune responses to 73 active tuberculosis

74 We supplemented data from our previously reported TST transcriptional responses (8) to provide a 75 total sample size of 51 people with microbiologically confirmed pulmonary TB who were within one 76 month of commencing anti-tuberculous chemotherapy (Table 1, Fig. S1A, B). We evaluated disease 77 severity using a published radiographic scoring system which incorporates extent of disease and the 78 presence of cavitation on chest x-ray (9). In order to capture the inter-individual variation in immune 79 response to the mycobacterial challenge, outlier profile analysis (10) was used to identify transcripts 80 in the TST of each individual that were significantly enriched compared to gene expression in control 81 data from skin biopsies at the site of saline injections. The integrated list of outlier genes statistically 82 enriched in TST samples compared to control saline samples from all 51 individuals defined an active 83 TB TST transcriptome comprised of 3222 transcripts. This analysis revealed that although some aspects of the TST response are consistent in all people, there is also considerable variability 84 between individuals (Fig. S1C). The 3222 transcripts identified by this approach, were enriched for 85 86 canonical pathways involved in cell mediated responses, consistent with our previous description of 87 the TST gene signature identified by conventional differential gene expression analysis (5, 8) (Fig. 88 S1D).

# Reduced type I interferon activity in the TST transcriptome is associated with increased severity of human TB disease

Next, we sought to identify immunological pathways correlated with disease severity. We identified individual genes in the TST transcriptome that showed statistically significant correlations with the

Protective type I interferon responses in mycobacterial infection

93 radiographic severity score. We subjected these genes to Ingenuity Pathway Analysis upstream 94 regulator analysis to collate groups of co-regulated genes (Fig. 1A and Fig. S2A). These were 95 annotated by their upstream regulators at the level of cytokines, transmembrane receptors, kinases 96 and transcriptional regulators, representing the key components of signalling pathways which 97 mediate immune responses. To provide increased confidence that these modules represented co-98 regulated genes in each molecular pathway, we retained only those that had significantly greater co-99 correlated expression than modules of genes randomly selected from our TST transcriptomes (11). 100 111 modules were identified among genes inversely correlated with radiographic TB severity, 101 suggesting they may contribute to host protection against severe disease (Fig. 1A-C and Fig. S2B). 102 These included transcriptional modules representing pro-inflammatory cytokine activity (tumour 103 necrosis factor alpha and interleukin (IL)1 beta), interferon gamma and T cell activity, consistent with 104 existing evidence predominantly supporting their protective roles in TB (12) (Fig. 1B). In addition, we 105 found enrichment of multiple co-regulated gene networks attributed to type I interferon signalling, 106 suggesting that type I interferon responses may also contribute to host protection in mycobacterial 107 infection (Fig. 1B, C). Interferon gamma was also predicted to regulate one of only two small putative 108 networks within genes positively correlated with disease severity; the other driven by TCL1A, an AKT 109 kinase activator that promotes cellular survival (13) (Fig. S2C).

110 To validate the immunological responses predicted to be associated with disease severity by 111 upstream regulator analysis, we quantified the expression of two independently derived and largely 112 non-overlapping type I interferon inducible gene modules reflecting the biological activity of type I interferons (Table S1) (5, 8), within the TB TST transcriptome (Fig. 1D). This provided independent 113 validation of the inverse relationship between type I interferon responses and radiographic severity 114 115 of TB (Fig. 1E), suggestive of a host-protective role. By contrast, the expression of the entire TST 116 transcriptome and that of three distinct independently derived interferon gamma inducible gene 117 modules (5) (Table S1) did not correlate with disease severity (Fig. S3).

117 modules (5) (Table S1) did not correlate with disease severity (Fig. S3).

# 118 stat2 CRISPant zebrafish larvae exhibit increased susceptibility to *M. marinum* infection

119 The TST transcriptome does not solely reflect anti-mycobacterial T cell memory (4) and type I 120 interferons are primarily induced following activation of innate immune recognition pathways (14). 121 Therefore, to evaluate whether impaired type I interferon responses cause more severe 122 mycobacterial disease, we exploited the zebrafish larval *M. marinum* infection model, which allows 123 exclusive assessment of innate immunity (7). The mammalian canonical type I interferon signalling 124 pathway is highly conserved in zebrafish (15, 16) (Fig. 2A). First, we confirmed that intravenous 125 M. marinum infection of wild type zebrafish larvae induces a type I interferon response, as evidenced by enrichment for two distinct independently derived transcriptional modules reflecting type I 126 127 interferon activity (11, 16) (Table S1) within genome-wide transcriptomic data obtained after four 128 days of mycobacterial growth (Fig. 2B, C). To block downstream type I interferon signalling we used 129 CRISPR-mediated mutagenesis of *stat2*, a subunit of the interferon stimulated gene factor (ISGF)3, 130 the principal transcription factor complex which induces expression of type I interferon stimulated 131 genes (ISG) (17–19), for which there is a single zebrafish orthologue (15) (Fig. 2A). Injection of three 132 guide RNA/Cas9 ribonucleoprotein (RNP) complexes each targeting a distinct stat2 exon, into one 133 cell stage wild type zebrafish embryos led to >90% efficient mutagenesis, confirmed by next-134 generation sequencing (Fig. S4A and Fig. S5A). We verified loss of functional downstream type I 135 interferon signalling by showing that induction of the classical ISG Mxa (16, 19) by recombinant 136 interferon phi 1, measured by expression of a reporter mxa:mCherry transgene, was significantly 137 attenuated in stat2 CRISPants compared to siblings injected with "scrambled" (negative control) 138 RNPs designed to lack genomic targets (Fig. S4B and Fig. S5B-C). stat2 CRISPants developed 139 normally up to five days post-fertilisation (Fig. S5B).

140 There was no difference in survival of *M. marinum* infected stat2 CRISPants and scrambled RNP 141 injected siblings (Fig. 3A, B) within the timeframe of our experiments. However, mycobacterial 142 burden, the number of bacterial foci and the spatial dissemination of bacteria, determined by 143 quantitation of fluorescent foci of *M. marinum*, were all significantly higher in intravenously infected 144 stat2 CRISPants compared to control RNP injected siblings, indicative of more severe disease (Fig. 145 3A, C-E). These findings are consistent with a host protective role for type I interferons in 146 mycobacterial infection, as suggested by our observation of an association between reduced type I 147 interferon activity and increased disease severity in human TB (Fig. 1).

Protective type I interferon responses in mycobacterial infection

# 148 Steady state neutrophil numbers are reduced in *stat2* CRISPant zebrafish larvae

149 Macrophages are critically important for control of *M. marinum* infection in zebrafish larvae (20-22) 150 and neutrophils may also contribute to mycobacterial killing (23, 24). Therefore, to investigate the 151 mechanisms by which stat2 deficiency leads to worse mycobacterial infection we used transgenic 152 zebrafish lines with fluorescent immune cell lineages to generate stat2 CRISPants that have 153 fluorescent macrophages or neutrophils. First, we asked whether stat2 disruption impacted steady 154 state macrophage or neutrophil numbers. We demonstrated by quantitative fluorescence 155 microscopy, using integrated fluorescence as a surrogate for cell number, that stat2 deficiency did 156 not affect baseline macrophage numbers (Fig. 4A, B). However, it was associated with reduced 157 neutrophil numbers (Fig. 4C, D).

# Recruitment of macrophages but not neutrophils to the site of sterile injury is stat2 dependent

160 Type I interferons have previously been shown to influence cellular migration (14, 25). Therefore, 161 we tested macrophage and neutrophil recruitment in stat2 CRISPants using a tailfin transection 162 model of sterile injury, most commonly used to evaluate neutrophil recruitment (26) (Fig. S4C). The 163 timing of neutrophil homing to the site of sterile tail fin transection was normal in *stat2* CRISPants, 164 with maximal accumulation at six hours and dissipation of recruited cells becoming evident by 24 hours, similar to that of control RNP injected embryos (Fig. 5A, B) and in keeping with previous 165 166 studies (26, 27). Despite baseline neutropenia, the number of neutrophils at the wound site at the 167 point of maximal recruitment in stat2 CRISPants exceeded that of control RNP injected embryos. 168 But by 24 hours the number of neutrophils at the injury site was significantly reduced in stat2 169 CRISPants, likely reflecting the attenuated increase in total neutrophil numbers in response to the 170 acute inflammatory challenge (Fig. 5C, D).

171 As previously reported, macrophage recruitment to the tail wound site was slower than that of 172 neutrophils (27, 28). Very few macrophages were present at the tailfin transection site by one hour 173 in either stat2 disrupted or control transgenic larvae, but recruitment progressively increased until 24 174 hours in both groups (Fig. 6). Fewer macrophages were found in the vicinity of the wound site at all 175 time points post-injury in stat2 CRISPant transgenic embryos compared to control RNP injected 176 siblings, the majority being located outwith the tailfin (Fig. 6). Taken together these data suggest that 177 stat2 is necessary for macrophage recruitment but non-essential for neutrophil recruitment to a 178 sterile injury site. In addition, baseline neutropenia did not impact the number of cells localised to the 179 wound at peak neutrophil recruitment.

# 180 Recruitment of myeloid cells to the site of *M. marinum* infection is *stat2* dependent

181 Next we focused on macrophage recruitment to the site of mycobacterial infection because this has 182 been reported to be crucial for control of *M. marinum* growth in zebrafish larvae (21). We found a 183 significant reduction in the number of macrophages recruited to the site of localised hindbrain 184 M. marinum infection in stat2 deficient transgenic zebrafish larvae compared to their counterparts 185 injected with scrambled RNPs (Fig. S4D and Fig. 7A, B). We then evaluated whether stat2 disruption 186 affected recruitment of neutrophils to the site of mycobacterial infection. We found that in contrast to 187 their normal peak recruitment to a sterile wound, the number of neutrophils attracted to the site of 188 mycobacterial disease was also significantly diminished in *stat2* CRISPants (Fig 7C, D). Collectively, 189 these results demonstrate that myeloid cell recruitment to the site of *M. marinum* infection is stat2 190 dependent.

191 In total, the recruitment studies suggest that *stat2* disruption leads to a broad defect in macrophage 192 recruitment to both infectious and non-infectious inflammatory foci. By contrast, *stat2* is non-essential 193 for neutrophil migration to sterile injury. The latter finding is consistent with defective migration, rather 194 than neutropenia, being the principal mechanism for reduced neutrophil numbers at the site of 195 *M. marinum* infection.

# 196 **Discussion**

We have taken an innovative approach, combining molecular and systems level evaluation of human
 immune responses to a standardised experimental challenge, to identify master regulators of

Protective type I interferon responses in mycobacterial infection

199 biological pathways associated with TB disease severity. We experimentally validated host factors 200 responsible for differences in phenotype using a relevant, tractable animal model which represents 201 a natural host-pathogen pairing (7). Molecular interrogation of human in vivo responses to Mtb 202 revealed that reduced type I interferon activity within the TST transcriptome was associated with 203 worse pulmonary disease. Deficient type I interferon signalling, achieved by genetic disruption of 204 stat2, led to more severe mycobacterial infection in zebrafish larvae, via a mechanism involving 205 impaired recruitment of macrophages and neutrophils to the site of disease and reduced neutrophil 206 numbers at baseline. Taken together our results demonstrate an important role for type I interferon 207 responses in contributing to innate immune protection against mycobacterial disease.

208 Peripheral blood interferon-inducible gene expression that diminishes with successful treatment is 209 detectable in human active TB (29-31). These transcriptional signatures comprise both type I and 210 type II interferon inducible genes but have mainly been interpreted as type I interferon responses, 211 fostering the view that type I interferons are detrimental to the host in human TB. Mouse data 212 predominantly suggest that type I interferon responses contribute to increased susceptibility to 213 mycobacterial infection by mechanisms including antagonism of IL1 mediated protection (32-34) 214 and reduced responsiveness of macrophages to interferon gamma (35). However, this phenotype 215 has not been universally observed, likely due to differences in host and pathogen genetics (36). 216 Moreover, impaired type I interferon responses are generally associated with relatively minor 217 differences in bacterial burden or survival (36). Of note, Mtb is not a natural mouse pathogen, and 218 this approach may not model host-pathogen interactions in human TB faithfully (37).

219 In support of a protective role for type I interferons, adjunctive interferon alpha therapy in addition to 220 conventional anti-tuberculous antibiotic treatment led to symptomatic and radiological improvement, 221 with a reduction in bacterial burden in respiratory tract samples, in small-scale human studies (38-222 40). In keeping with this, an early peripheral blood type I interferon-inducible gene signature predicts 223 successful BCG-induced protection of macagues from subsequent Mtb challenge (41). Type I 224 interferon mediated restriction of mycobacterial growth in in vitro granulomas comprising collagen 225 impregnated microspheres containing Mtb infected human peripheral blood mononuclear cells 226 (PBMC) (42) also suggests that type I interferon responses benefit the host.

227 Our observation of reduced recruitment of macrophages to the site of disease is likely the most 228 important factor driving increased susceptibility to *M. marinum* infection in *stat2* CRISPants. 229 Although macrophages have been implicated in the dissemination of *M. marinum* in zebrafish larvae 230 (20, 43), reduction of total macrophage numbers, impaired macrophage migration to the site of 231 mycobacterial infection or failure to control intracellular bacterial growth within macrophages have 232 all been associated with poor outcome (20-22, 44, 45). In contrast, increasing macrophage numbers 233 via augmentation of M-CSF signalling either pre- or post-granuloma formation, promotes resistance 234 to M. marinum infection by reducing granuloma necrosis, with consequent curtailment of 235 extracellular mycobacterial growth (21). The recent report that human genetically inherited CCR2 236 deficiency is associated with reduced pulmonary recruitment of monocytes, resulting in depleted 237 numbers of functionally normal alveolar macrophages and increased susceptibility to mycobacteria, 238 is also consistent with the notion that adequate numbers of macrophages are important for protective 239 anti-mycobacterial immunity (46).

240 The reduction in neutrophils present at the site of *M. marinum* infection in *stat2* CRISPants may have 241 arisen due to baseline neutropenia, defective migration or both combined. On the basis that steady 242 state neutropenia did not affect the timing and magnitude of peak neutrophil recruitment to sterile 243 injury, impaired migration is probably the main driver of this phenotype, which likely also contributed 244 to increased severity of mycobacterial disease. Previous data show that reduced access of 245 neutrophils to mycobacteria leads to increased bacterial burden in a zebrafish line in which 246 neutrophils express mutant cxcr4, resulting in peripheral neutropenia and impaired neutrophil 247 recruitment to sites of inflammation, due to their retention in haematopoietic tissue (23, 47).

Our study has some limitations. We were not able to address the reasons for variation in type I interferon activity in our human cohort. Serum samples for measurement of autoantibodies to type I interferons are not available and our sample size is insufficient for robust detection of associations between genetic variation and the expression levels of type I interferon signalling pathway genes. We were also unable to completely disentangle whether reduced neutrophil recruitment to the site of *M. marinum* infection was a consequence of neutropenia or impaired migration. We have not

Protective type I interferon responses in mycobacterial infection

determined the mechanism by which attenuated type I interferon signalling leads to reduced myeloid cell recruitment to *M. marinum*. The expression of several chemokines is type I interferon inducible (*25, 48, 49*) and the CCR2-CCL2 and CXCR3-CXCL11 chemokine axes are known to be involved in macrophage recruitment to *M. marinum (43, 50)*. Future studies are required to test the hypothesis that *stat2* mutagenesis disrupts chemokine-mediated cellular recruitment to the site of mycobacterial disease. Nonetheless, our work provides new insights into type I interferon mediated host protection against mycobacterial infection.

261 Variation in type I interferon responses may arise due to genetically or epigenetically encoded 262 variation in the immune response to Mtb, neutralising type I interferon auto-antibodies, burden and 263 virulence of the mycobacterial inoculum and stochasticity in the immune response pathway following 264 exposure (51-55). A central tenet of all these possibilities is that differences in the host immune 265 response to Mtb lead to differences in disease severity. Our findings have potential implications for 266 risk stratification of individuals in whom any of these mechanisms predisposing to low type I 267 interferon activity are identified. In active TB, such individuals could be targeted for longer or more 268 intensive drug regimens, or adjunctive type I interferon therapy delivered to the respiratory tract, to 269 mitigate against severe disease. Early intervention with type I interferon treatment, before destruction 270 of the lung parenchyma, is likely to be crucial to augment macrophage containment of Mtb, but timing 271 and duration of therapy will require evaluation in relatively large-scale experimental medicine trials.

#### 272 MATERIALS AND METHODS

#### 273 Ethics statement

The study was approved by the London Bloomsbury Research Ethics Committee (16/LO/0776). Written informed consent was obtained from all participants.

#### 276 Study design

277 We aimed to identify master regulators of human immune responses that correlate with severity of 278 TB disease, using transcriptional profiling of biopsies from the TST as a surrogate for immune 279 responses to TB in the lung and to test causation for observed associations by genetic manipulation 280 of identified upstream regulator molecules in the zebrafish larval mycobacterial infection model. To 281 encompass a broad spectrum of disease severity we recruited 51 adults (>18 years) from four London hospitals, newly diagnosed with smear or culture positive pulmonary TB, who were within 282 283 four weeks of starting treatment. This is in keeping with the median sample size of previous studies 284 which have successfully demonstrated a relationship between severity of TB disease and 285 immunological parameters (29, 56-59). Individuals with coincident human immunodeficiency virus infection, malignancy, taking immunomodulatory therapy, a history of immunization within the 286 287 preceding two weeks or previous keloid formation, or unable to give informed consent were 288 excluded. Study participants underwent intradermal injection of 0.1 ml of two units of tuberculin (AJ 289 Vaccines) or saline in the volar aspect of the forearm as previously described (4, 5, 8). At 48 hours 290 clinical induration at the injection site was measured, immediately prior to sampling by 3mm punch 291 biopsy as previously described (4, 5). Additional saline samples from individuals with cured or latent 292 TB, BCG vaccine recipients and healthy volunteers have been described previously (8).

# 293 **RNA** purification from skin biopsy and zebrafish embryo samples

294 Skin biopsies were homogenized as previously described *(8)*. Pooled zebrafish embryos (25-30 per 295 experimental condition) collected in Qiazol (Qiagen) were homogenized in CK14 lysing kit tubes 296 (Bertin Instruments) using a Precellys Evolution homogenizer (Bertin Instruments) for 10-20 seconds 297 at 5500 rpm. Total RNA from skin biopsies and zebrafish samples was purified using the RNEasy 298 mini and micro kits (Qiagen), respectively, according to the manufacturer's instructions. Genomic 299 DNA was removed using the TURBO DNA-free kit (ThermoFisher).

# 300 Transcriptional profiling of skin biopsy and zebrafish larval samples

301 Genome-wide mRNA sequencing was performed as previously described *(8, 60)*. Complementary 302 DNA (cDNA) libraries were prepared using the KAPA HyperPrep kit (Roche). Sequencing was 303 performed in paired-end mode with the NextSeq 500 High Output 75 Cycle Kit (Illumina) using the 304 NextSeq500 system (Illumina) according to the manufacturer's instructions, generating a median of 305 22 million (range 12.3-27.9 million) 41 base pair reads per human sample and 16.8 million (range

Protective type I interferon responses in mycobacterial infection

306 15.1-18.1 million) reads per zebrafish sample. Transcript alignment and quantitation against the 307 Ensembl GRCh38 human genome assembly release 100 or GRCz11 zebrafish genome assembly release 104 was performed using Kallisto (61). Transcript-level output counts and transcripts per 308 309 million (TPM) values were summed on gene level and annotated with Ensembl gene ID, gene name, 310 and gene biotype using the R/Bioconductor packages tximport and BiomaRt (62, 63). Downstream 311 analysis was performed using R 3.6.3 on log2 transformed TPM values for protein-coding genes 312 only. TPM values <0.001 were set to 0.001 prior to log2 transformation. To determine the need for 313 and effect of batch correction in the human data, principal component analysis (PCA) was performed 314 using the prcomp R function on the integrated list of 6802 genes with the 10% lowest variance in 315 expression for each library preparation date. This revealed separation of three samples in PC1, likely 316 accounted for by lower RNA concentrations or RIN values compared to the rest of the dataset (Fig. 317 S1A). After batch correction performed using the ComBat function of the sva R package (64), 318 allocating samples with PC1 score <0 and >0 to separate batches, this was no longer evident (Fig. 319 S1B).

# 320 Radiographic quantitation of TB severity

321 Disease severity was evaluated by estimating the extent of radiographic abnormalities and whether 322 cavitation was present on chest x-ray at the time of diagnosis, as previously described (8, 9).

# 323 Outlier analysis

324 The BioBase Bioconductor R package was used to perform outlier analysis based on the z-score 325 outlier detection (ZODET) algorithm (10), to identify transcripts in each TST sample whose expression was significantly higher than the mean expression in control saline samples (>2SD, 326 327 p value <0.05), with a fold difference filter of >1 log2. Chi-squared tests implemented in R were then 328 used to identify outlier genes statistically enriched in TST samples compared to saline samples, 329 using a p value <0.05. To avoid type 2 error no correction for multiple testing was used in this 330 analysis. In instances where multiple Ensembl gene IDs were associated with a single gene symbol, 331 duplicate gene symbols were removed to retain the replicate with the highest expression for each 332 sample.

# 333 Pathway enrichment analysis

The biological pathways represented by the TST transcriptome were identified by Reactome pathway enrichment analysis using XGR as previously described *(65, 66)*. For visualization, 15 pathway groups were identified by hierarchical clustering of Jaccard indices to quantify similarity between the gene compositions of each pathway. For each group the pathway term with the largest number of annotated genes was then selected as representative of enriched biology.

# 339 Upstream regulator analysis

340 TST transcriptome genes whose expression was significantly correlated with radiographic severity 341 of TB disease were identified by Spearman rank correlation, p value <0.05, without correction for 342 multiple testing, to prevent type 2 error. Genes positively and negatively correlated with disease 343 severity were separately subjected to Ingenuity Pathway Analysis (Qiagen) to identify upstream molecules responsible for their transcriptional regulation. This analysis was restricted to molecules 344 345 annotated with the following functions: cytokine, transmembrane receptor, kinase and transcriptional 346 regulator, representing the canonical components of pathways which mediate transcriptional 347 reprogramming in immune responses. Enriched molecules with an adjusted p value <0.05 were 348 considered statistically significant.

# 349 Upstream regulator functional modules

350 TST gene modules representing the functional activity of their upstream molecule were identified as 351 previously described (11). In brief, we calculated the average correlation coefficient for pairwise 352 correlations of the expression levels of the target genes associated with each predicted upstream 353 regulator. We compared these to the distribution of average correlation coefficients obtained from 354 100 iterations of randomly selecting equivalent sized groups of genes from the TST transcriptome. 355 Only target gene modules with average correlation coefficients higher than the mean of the 356 distribution of equivalent sized randomly selected groups by  $\geq 2$  SD (Z score  $\geq 2$ ) with false discovery 357 rate <0.05, were retained. We visualised these upstream regulator modules as network diagrams

Protective type I interferon responses in mycobacterial infection

using the Force Atlas two algorithm in Gephi v0.9.2 (67), depicting all statistically over-represented molecules (false discovery rate <0.05) predicted to be upstream of  $\geq$ 4 target genes.

# 360 Transcriptional modules

Interferon inducible transcriptional module gene lists are provided in Table S1. Independently derived 361 362 human type I and type II interferon inducible gene modules were described previously (5, 8, 11). 363 Two further modules were derived to distinguish type I or type II interferon inducible gene expression 364 using published transcriptional data for primary human keratinocytes stimulated with a selection of cytokines (Gene Expression Omnibus accession: GSE36287) (68). Stimulus-specific modules for 365 366 type I interferon (interferon alpha) and type II interferon (interferon gamma) were derived by selecting 367 genes overexpressed >4-fold in the cognate cytokine condition relative to all non-cognate conditions 368 combined (paired t test with  $\alpha$  of p<0.05 without multiple testing correction), excluding genes also 369 induced by each non-cognate cytokine condition, using the same criteria. The babelgene R package (https://igordot.github.io/babelgene/) was used to convert human gene symbols to their respective 370 371 zebrafish orthologues to generate the zebrafish Stat1 module, excluding zebrafish genes reported 372 to be an orthologue of more than one human gene. The zebrafish type I interferon inducible gene 373 module comprises 360 genes whose expression was significantly induced (≥2 fold, adjusted p value 374 <0.05) six hours after intravenous injection of three day post-fertilisation (dpf) larvae with 1 nl of 375 recombinant interferon phi 1 protein (1 mg/ml) as previously described (16).

# 376 Venn diagrams

377 Area-proportional Venn diagrams visualizing the overlap between constituent genes in 378 transcriptional modules were generated using BioVenn *(69)*.

# 379 Zebrafish husbandry

380 Zebrafish were raised and maintained at 28.5°C following a 14/10 light/dark cycle according to standard protocols (70) in University College London (UCL) and Neuro-PSI Zebrafish Facilities. All 381 work was approved by the British Home Office (Project License PP8780756) and the French Ministry 382 383 for Research and Higher Education (Project Licence 39238). All experiments were performed in 384 accordance with the relevant guidelines and regulations, on larvae up to five days post-fertilisation, before they are protected under the Animals (Scientific Procedures) Act. Adult zebrafish were 385 386 spawned to collect embryos for experiments. Table S2 lists the lines used in this study (26, 71, 72). 387 Embryos were maintained at 28.5°C in egg water containing 60 µg/ml Tropic Marin Sea Salt 388 (Norwood Aquarium) and anaesthetised with eqg water containing 200 µg/ml buffered tricaine (3-389 aminobenzoic acid ethyl ester) (Sigma-Aldrich) during injection, tail fin transection and imaging. 390 Larvae used for in vivo imaging were maintained in egg water supplemented at 24 hours post-391 fertilisation (hpf) with 0.003% PTU (1-phenyl-2-thiourea) (Sigma-Aldrich) to inhibit melanisation.

# 392 CRISPant Generation

393 To maximise the likelihood of loss of functional protein we employed a previously described triple-394 exon targeting approach (73), with the modification that Cas9 protein was not diluted before use. CRISPR RNA (crRNA) (Alt-R CRISPR-Cas9 crRNA), tracrRNA (Alt-R CRISPR-Cas9 tracrRNA) and 395 396 recombinant Cas9 protein (Alt-R Streptococcus pyogenes Cas9 Nuclease V3) were obtained from 397 Integrated DNA Technologies (IDT). Three pre-designed crRNAs targeting distinct exons were 398 selected for the stat2 gene, prioritizing those that targeted early, asymmetric (not divisible by three) 399 exons common to both protein-coding transcripts, with low off-target and high on-target scores and 400 in a genomic position which allowed design of primers flanking the target site to generate a ~200 bp 401 amplicon, for verification of mutagenesis by next generation sequencing (MiSeg). crRNA sequences 402 and genomic locations are provided in Table S3. To generate gRNAs equal volumes of crRNA and 403 tracrRNA diluted to 61 µM in Duplex buffer (IDT) were annealed at 95°C for 5 minutes. Equal 404 volumes of gRNA (61 µM) and Cas9 protein (61 µM) were incubated at 37°C for 5 minutes to 405 assemble separate 30.5 µM ribonucleoproteins (RNPs) for each target. Equal volumes of the three RNPs were pooled, prior to injection giving a final concentration of 10.2 µM for each. Negative control 406 407 "scrambled" crRNAs computationally designed to be non-targeting (Alt-R CRISPRCas9 Negative 408 Control crRNA #1, #2, #3) were prepared and pooled as described above. 0.5 nl of pooled stat2 409 RNPs or scrambled RNPs was injected into the yolk sac of single-cell stage wild type or transgenic 410 zebrafish embryos before cell inflation as previously described (73). After injections embryos were

Protective type I interferon responses in mycobacterial infection

411 transferred into sterile petri dishes with fresh egg water and maintained at 28.5°C to the appropriate 412 age for experiments, as described below.

# 413 Interferon phi 1 stimulation

Three dpf *stat2* CRISPant *Tg(mxa:mCherry)* larvae and scrambled RNP injected siblings were injected in the coelomic cavity with 1 nl of recombinant zebrafish interferon phi 1 protein (1.25 mg/ml), produced as previously described (*74*). *stat2* and control CRISPants were shuffled so that injections were performed blindly. Bovine serum albumin (BSA) (1.25 mg/ml) was injected as a control. Interferon phi 1 and BSA solutions were supplemented with 0.2% phenol red (Sigma-Aldrich) to visualize the inoculum. Induction of Mxa reporter expression was determined by fluorescence microscopy 24 hours post-injection.

# 421 *M. marinum* infection

422 M. marinum M strain expressing the pmsp12 mWasabi (75) or psMT3 mCherry plasmid (76) was 423 cultured using Middlebrook 7H10 agar (Becton Dickinson and Company) supplemented with 0.5% 424 oleic acid/albumin/dextrose/catalase (OADC) (Becton Dickinson and Company), 0.5% glycerol 425 (Sigma-Aldrich) and hygromycin (50 µg/ml) (Fisher Scientific). To generate bacterial suspensions for 426 injection, *M. marinum* from agar plates was cultured statically at 28.5°C for 24-36 hours in 10 ml 427 7H9 broth (Becton Dickinson and Company) supplemented with Middlebrook 10% 428 albumin/dextrose/catalase (ADC) (Becton Dickinson and Company) and hygromycin (50 µg/ml) 429 (Fisher Scientific). Bacteria were harvested at mid-log growth (optical density (OD)600nm 0.7-1), 430 (OD)600nm 1 representing 10<sup>8</sup> colony forming units (cfu)/ml, washed three times in phosphate buffered saline (PBS) (Gibco) and resuspended in 2% polyvinylpyrrolidone (PVP)40 (Sigma-431 432 Aldrich)/PBS containing 10% phenol red (Sigma-Aldrich) to aid visualisation of injections (77).

433 Zebrafish embryos were manually dechorionated using jeweller's forceps (Dumont #5, World 434 Precision Instruments) prior to bacterial infection. To generate systemic infection, 400 cfu 435 *M. marinum* in a volume of 1 nl were microinjected into the caudal vein of embryos staged at 436 28-30 hpf. Four days post-infection, embryos were either subjected to fluorescence microscopy to 437 measure disease severity or 25-30 per condition pooled and harvested in Qiazol (Qiagen) for 438 evaluation of immune responses by RNAseq. To generate localised infection, 200 cfu *M. marinum* 439 in a volume of 1 nl were injected into the hindbrain ventricle (HBV) of two dpf zebrafish larvae. 440 Cellular recruitment was evaluated by fluorescence microscopy at 6-18 hours post-infection.

# 441 Tailfin transection

442 Tailfin transections were performed as described previously (26, 78). Briefly, live anaesthetised three 443 dpf zebrafish larvae were transferred with a 1 ml Pasteur pipette (Scientific Laboratory Supplies) to 444 a sterile petri dish containing 2% agarose (Bioline). Transections of the caudal fin were performed 445 using a sterile microscalpel (World Precision Instruments) by applying steady downward pressure to 446 create the incision at the boundary with the notochord. Following injury, larvae were rinsed in egg 447 water, and maintained in individual wells of a 96-well tissue culture plate (TPP) at 28.5°C until live 448 imaging to quantify neutrophil or macrophage recruitment to the site of injury at 1, 6 and 24 hours-449 post-wound (hpw).

# 450 Fluorescence microscopy

451 All fluorescence microscopy was performed on live, anasethised larvae. For quantitation of bacterial 452 burden and dissemination four days post-infection, steady state neutrophil numbers at two dpf and 453 cellular recruitment at 2-4 dpf, larvae were imaged using an M205FA stereofluorescence microscope 454 (Leica) with a 1x objective. Larvae were imaged on a flat 1% agarose plate for quantitation of severity 455 of mycobacterial infection and steady state neutrophil numbers and a 96-well tissue culture plate 456 (TPP) in which the wells were coated with 1% agarose, for cellular recruitment to tailfin transection. 457 Micro-wells were created in 1% agarose using a Stampwell Larvae 1 device (Idylle) for optimal 458 positioning of 2-3 dpf larvae for imaging of cellular recruitment to hindbrain ventricle *M. marinum* 459 infection. Brightfield and fluorescence images were captured using a DFC365 FX camera (Leica) 460 and exported as 16-bit Tagged Image Format (TIF) files for analysis. For quantitation of steady state 461 macrophage numbers three dpf larvae were imaged in 96-well alignment plates (Funakoshi) 462 containing 75 µl egg water per well using a high-content wide-field fluorescence microscope 463 (Hermes, IDEA Bio-Medical) with a 4x objective, capturing five z planes 50.6 µm apart in four

Protective type I interferon responses in mycobacterial infection

464 contiguous fields of view per embryo. We created an ImageJ macro to semi-automate generation of 465 single maximum intensity projection z-stack montages from the Hermes images, which were saved 466 as 16-bit TIF files for analysis (Table S4. Mxa reporter expression was recorded with an EVOS M7000 microscope (ThermoFisher) equipped with a 2x/NA0.06 objective and Texas Red 467 468 fluorescence cube. Larvae were positioned laterally in micro-wells created in 2% agarose with an in-469 house-printed stamp. A single fluorescence plane was recorded as the depth of field is sufficient to 470 capture the entire larva. Transmitted light images were also recorded and both were exported as 16-471 bit TIF files.

# 472 Image analysis

To quantify bacterial burden, number of bacterial foci and spatial distribution of bacteria, images 473 474 were analysed using custom QuantiFish software, previously developed in our group, to enable rapid 475 quantitation of fluorescent foci in zebrafish larvae (79). Mxa reporter fluorescence was measured 476 with ImageJ. Transmitted and fluorescence images were stacked. Images were slightly rotated to 477 horizontality where necessary. A 600x100 pixel rectangular region of interest was defined on the 478 transmitted light image to encompass the entire gut and liver areas. Mean fluorescence intensity was 479 then measured on the fluorescence image. For quantitation of total cell number and recruitment of 480 fluorescent immune cells to the site of tailfin transection we developed a new custom Python script 481 which enables quantitation of integrated fluorescence within concentric zones (known as Sholl 482 circles) (80). To achieve this, the script leverages the OpenCV, NumPy (81), Matplotlib, SciPy 483 (http://www.scipy.org), scikit-image (82) and pandas Python libraries to facilitate image processing and data extraction (Table S5. First the user is prompted to select a folder containing images for 484 485 analysis, as well as the file extensions corresponding to the brightfield and fluorescence images, which are essential for the subsequent steps. The script then iterates through each pair of brightfield 486 487 and fluorescent images prompting the user to define two points on the brightfield image, which serve 488 as the start and end positions between which to create concentric circular regions (80) on the 489 corresponding fluorescence image. The script employs the image processing techniques described 490 in Table S5 to quantify integrated fluorescence of the entire image and that within each region, as a 491 surrogates for the total number of immune cells and the number at each spatial location, respectively 492 and generates output files containing this information. Integrated fluorescence within the first zone 493 (the wound site) and distance from the site of tailfin transection of the zone in which the maximal 494 integrated fluorescence (a surrogate for the highest cell numbers) was detected (identified manually) 495 were used as measures of immune cell recruitment for each zebrafish larva. The number of cells 496 recruited to the site of hindbrain *M. marinum* infection was quantified by manual counting.

# 497 **Genotyping by next generation sequencing**

# 498 Genomic DNA extraction

Genomic DNA was extracted from anasethetised individual zebrafish larvae using the modified hot
sodium hydroxide and Tris (HotSHOT) method as previously described (*73, 83*). Briefly, larvae in
96-well plates were incubated in 50 µl base solution (25 mM KOH, 0.2 mM EDTA in water) at 95°C
for 30 min then cooled to room temperature, before addition of 50 µl neutralization solution (40 mM
Tris-HCL in water).

# 504 <u>PCR</u>

505 Extracted DNA (2 µl per 50 µl reaction) was subjected to PCR using Phusion High-Fidelity DNA Polymerase (New England Biolabs) (98°C for 30 seconds (s), once only, 40 cycles of 98°C for 10 s, 506 59°C for 30 s, 72°C for 20 s, 72°C for 10 minutes, once only). Sequences and genomic positions of 507 the primers used are provided in Table S3. Successful amplification of a single product of 508 approximately 300 bp was verified by 2% agarose (Bioline) Tris-borate-EDTA (TBE) containing 509 510 Redsafe (Chembio) gel electrophoresis. PCR products were purified using ExoSAP-IT Express 511 (ThermoFisher), concentration of purified DNA determined by Nanodrop spectrophotometer 512 (ThermoFisher) and samples diluted to 15-25 ng/µl for sequencing.

# 513 Next generation sequencing and data analysis

514 Sequencing was performed by the UCL Fish Genomic Service using the MiSeq Reagent Kit v2 (300-515 cycles) (Illumina) and the MiSeq system (Illumina) in paired end mode, according to the 516 manufacturer's instructions. Sequencing data were received as two FASTQ files (forward and

Protective type I interferon responses in mycobacterial infection

517 reverse) for each sample. Visual sequence analysis was performed using Geneious 10.2.6 518 (https://www.geneious.com) for initial verification of successful genome editing close to the PAM site. 519 Objective quantitation of the proportion of reads mutated and predicted to be frameshifted was 520 achieved using the ampliCan R package (84), which utilizes the FASTQ files and a metadata file 521 providing the amplicon, protospacer adjacent motif (PAM) and primer sequences (Table S3) and 522 sample information, as previously described (73). AmpliCan was run with default parameters, with 523 the exception that min freq = 0.005 (mutations at a frequency below this threshold were considered 524 a sequencing error) and average quality = 25. Mutations present in uninjected or scrambled RNP 525 injected control samples were not included as Cas9 induced mutations.

#### 526 Statistical analysis

527 Statistical analysis was performed using GraphPad Prism 9.3.1 for Windows (GraphPad Software) 528 and R3.6.3. Chi-squared tests were used to identify outlier genes statistically enriched in 529 transcriptomic data from TST samples compared to saline samples, with no correction for multiple 530 testing to avoid type 2 error. Spearman rank correlation was used to determine the strength of 531 relationship between TST transcriptome gene expression and TB disease severity (two-tailed), 532 transcript levels of upstream regulator target gene modules and TST random gene modules (one-533 tailed, positive correlation only) and mean expression of transcriptional modules in TST 534 transcriptomic data with severity of TB disease (two-tailed). The Benjamini-Hochberg correction 535 method for multiple comparisons was used to identify upstream regulator target gene modules with 536 average correlation coefficients significantly higher than the mean of the distribution of equivalent sized randomly selected gene modules by  $\geq 2$  SD (Z score  $\geq 2$ ) with false discovery rate <0.05. 537 538 Survival of stat2 CRISPant and control zebrafish larvae was compared using a log-rank (Mantel-539 Cox) test; a p value <0.05 was considered significant. On scatter plots horizontal lines represent 540 median values and error bars indicate the interquartile range. On box and whisker plots horizontal 541 lines represent median values, box limits indicate the interguartile range and whiskers extend 542 between the 5th and 95th percentiles of the data. Two-tailed Mann-Whitney tests were used for two 543 group comparisons of unpaired data; a p value <0.05 was considered significant. Where p values 544 are not presented on graphs, \* denotes p<0.05.

#### 545 **REFERENCES AND NOTES**

546 1. A. K. Coussens, S. M. A. Zaidi, B. W. Allwood, P. K. Dewan, G. Gray, M. Kohli, T. Kredo, B. J.
547 Marais, G. B. Marks, L. Martinez, M. Ruhwald, T. J. Scriba, J. A. Seddon, P. Tisile, D. F. Warner, R.
548 J. Wilkinson, H. Esmail, R. M. G. J. Houben, International Consensus for Early TB (ICE-TB) group,
549 Classification of early tuberculosis states to guide research for improved care and prevention: an
550 international Delphi consensus exercise. *Lancet Respir. Med.* 12, 484–498 (2024).

551 2. A. M. Cadena, S. M. Fortune, J. L. Flynn, Heterogeneity in tuberculosis. *Nat. Rev. Immunol.* **17**, 691–702 (2017).

3. S. H. E. Kaufmann, C. Lange, M. Rao, K. N. Balaji, M. Lotze, M. Schito, A. I. Zumla, M. Maeurer,
Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. *Lancet Respir. Med.* 2, 301–320 (2014).

4. G. S. Tomlinson, T. J. Cashmore, P. T. G. Elkington, J. Yates, R. J. Lehloenya, J. Tsang, M. Brown, R. F. Miller, K. Dheda, D. R. Katz, B. M. Chain, M. Noursadeghi, Transcriptional profiling of innate and adaptive human immune responses to mycobacteria in the tuberculin skin test. *Eur. J. Immunol.* **41**, 3253–3260 (2011).

560 5. L. C. K. Bell, G. Pollara, M. Pascoe, G. S. Tomlinson, R. J. Lehloenya, J. Roe, R. Meldau, R. F. 561 Miller, A. Ramsay, B. M. Chain, K. Dheda, M. Noursadeghi, In Vivo Molecular Dissection of the 562 Effects of HIV-1 in Active Tuberculosis. *PLoS Pathog.* **12**, e1005469 (2016).

6. M.-J. Kim, H. C. Wainwright, M. Locketz, L.-G. Bekker, G. B. Walther, C. Dittrich, A. Visser, W.
Wang, F.-F. Hsu, U. Wiehart, L. Tsenova, G. Kaplan, D. G. Russell, Caseation of human tuberculosis
granulomas correlates with elevated host lipid metabolism. *EMBO Mol. Med.* 2, 258–274 (2010).

566 7. L. Ramakrishnan, The zebrafish guide to tuberculosis immunity and treatment. *Cold Spring Harb. 12* 

Protective type I interferon responses in mycobacterial infection

567 Symp. Quant. Biol. **78**, 179–192 (2013).

8. G. Pollara, C. T. Turner, J. Rosenheim, A. Chandran, L. C. K. Bell, A. Khan, A. Patel, L. F. Peralta,
A. Folino, A. Akarca, C. Venturini, T. Baker, S. Ecker, F. L. M. Ricciardolo, T. Marafioti, C. UgarteGil, D. A. J. Moore, B. M. Chain, G. S. Tomlinson, M. Noursadeghi, Exaggerated IL-17A activity in
human in vivo recall responses discriminates active tuberculosis from latent infection and cured
disease. *Sci. Transl. Med.* 13, eabg7673 (2021).

9. A. P. Ralph, M. Ardian, A. Wiguna, G. P. Maguire, N. G. Becker, G. Drogumuller, M. J. Wilks, G.
Waramori, E. Tjitra, null Sandjaja, E. Kenagalem, G. J. Pontororing, N. M. Anstey, P. M. Kelly, A
simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary
tuberculosis. *Thorax* 65, 863–869 (2010).

577 10. D. L. Roden, G. W. Sewell, A. Lobley, A. P. Levine, A. M. Smith, A. W. Segal, ZODET: software
578 for the identification, analysis and visualisation of outlier genes in microarray expression data. *PloS*579 *One* 9, e81123 (2014).

11. A. Chandran, J. Rosenheim, G. Nageswaran, L. Swadling, G. Pollara, R. K. Gupta, A. R. Burton,
J. A. Guerra-Assunção, A. Woolston, T. Ronel, C. Pade, J. M. Gibbons, B. Sanz-Magallon Duque
De Estrada, M. Robert de Massy, M. Whelan, A. Semper, T. Brooks, D. M. Altmann, R. J. Boyton,
Á. McKnight, G. Captur, C. Manisty, T. A. Treibel, J. C. Moon, G. S. Tomlinson, M. K. Maini, B. M.
Chain, M. Noursadeghi, COVIDsortium Investigators, Rapid synchronous type 1 IFN and virusspecific T cell responses characterize first wave non-severe SARS-CoV-2 infections. *Cell Rep. Med.* **3**, 100557 (2022).

12. R. L. Kinsella, D. X. Zhu, G. A. Harrison, A. E. Mayer Bridwell, J. Prusa, S. M. Chavez, C. L.
Stallings, Perspectives and Advances in the Understanding of Tuberculosis. *Annu. Rev. Pathol. Mech. Dis.* 16, 377–408 (2021).

590 13. F. Paduano, E. Gaudio, A. A. Mensah, S. Pinton, F. Bertoni, F. Trapasso, T-Cell 591 Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. *Front.* 592 *Oncol.* **8**, 317 (2018).

593 14. F. McNab, K. Mayer-Barber, A. Sher, A. Wack, A. O'Garra, Type I interferons in infectious 594 disease. *Nat. Rev. Immunol.* **15**, 87–103 (2015).

595 15. C. Langevin, E. Aleksejeva, G. Passoni, N. Palha, J.-P. Levraud, P. Boudinot, The antiviral innate
596 immune response in fish: evolution and conservation of the IFN system. *J. Mol. Biol.* 425, 4904–
597 4920 (2013).

598 16. J.-P. Levraud, L. Jouneau, V. Briolat, V. Laghi, P. Boudinot, IFN-Stimulated Genes in Zebrafish
599 and Humans Define an Ancient Arsenal of Antiviral Immunity. *J. Immunol. Baltim. Md* 1950 203,
600 3361–3373 (2019).

17. K. Blaszczyk, H. Nowicka, K. Kostyrko, A. Antonczyk, J. Wesoly, H. A. R. Bluyssen, The unique
 role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. *Cytokine Growth Factor Rev.* 29, 71–81 (2016).

18. A. Begitt, M. Droescher, T. Meyer, C. D. Schmid, M. Baker, F. Antunes, K.-P. Knobeloch, M. R.
Owen, R. Naumann, T. Decker, U. Vinkemeier, STAT1-cooperative DNA binding distinguishes type
1 from type 2 interferon signaling. *Nat. Immunol.* **15**, 168–176 (2014).

19. J. W. Schoggins, Interferon-Stimulated Genes: What Do They All Do? *Annu. Rev. Virol.* **6**, 567– 584 (2019).

20. H. Clay, J. M. Davis, D. Beery, A. Huttenlocher, S. E. Lyons, L. Ramakrishnan, Dichotomous role
of the macrophage in early Mycobacterium marinum infection of the zebrafish. *Cell Host Microbe* 2,
29–39 (2007).

- 612 21. A. J. Pagán, C.-T. Yang, J. Cameron, L. E. Swaim, F. Ellett, G. J. Lieschke, L. Ramakrishnan,
- 613 Myeloid Growth Factors Promote Resistance to Mycobacterial Infection by Curtailing Granuloma 614 Necrosis through Macrophage Replenishment. *Cell Host Microbe* **18**, 15–26 (2015).
- 22. R. D. Berg, S. Levitte, M. P. O'Sullivan, S. M. O'Leary, C. J. Cambier, J. Cameron, K. K. Takaki,
  C. B. Moens, D. M. Tobin, J. Keane, L. Ramakrishnan, Lysosomal Disorders Drive Susceptibility to
- Tuberculosis by Compromising Macrophage Migration. Cell 165, 139–152 (2016).
- 618 23. C.-T. Yang, C. J. Cambier, J. M. Davis, C. J. Hall, P. S. Crosier, L. Ramakrishnan, Neutrophils
  619 exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria
  620 phagocytosed from infected macrophages. *Cell Host Microbe* 12, 301–312 (2012).
- 24. P. M. Elks, S. Brizee, M. van der Vaart, S. R. Walmsley, F. J. van Eeden, S. A. Renshaw, A. H.
  Meijer, Hypoxia inducible factor signaling modulates susceptibility to mycobacterial infection via a
  nitric oxide dependent mechanism. *PLoS Pathog.* 9, e1003789 (2013).
- 624 25. I. Rauch, M. Müller, T. Decker, The regulation of inflammation by interferons and their STATs. 625 *JAK-STAT* **2**, e23820 (2013).
- 626 26. S. A. Renshaw, C. A. Loynes, D. M. I. Trushell, S. Elworthy, P. W. Ingham, M. K. B. Whyte, A 627 transgenic zebrafish model of neutrophilic inflammation. *Blood* **108**, 3976–3978 (2006).
- 628 27. C. Gray, C. A. Loynes, M. K. B. Whyte, D. C. Crossman, S. A. Renshaw, T. J. A. Chico,
  629 Simultaneous intravital imaging of macrophage and neutrophil behaviour during inflammation using
  630 a novel transgenic zebrafish. *Thromb. Haemost.* **105**, 811–819 (2011).
- 631 28. F. Ellett, L. Pase, J. W. Hayman, A. Andrianopoulos, G. J. Lieschke, mpeg1 promoter transgenes
  632 direct macrophage-lineage expression in zebrafish. *Blood* **117**, e49-56 (2011).
- 29. M. P. R. Berry, C. M. Graham, F. W. McNab, Z. Xu, S. A. A. Bloch, T. Oni, K. A. Wilkinson, R.
  Banchereau, J. Skinner, R. J. Wilkinson, C. Quinn, D. Blankenship, R. Dhawan, J. J. Cush, A. Mejias,
  O. Ramilo, O. M. Kon, V. Pascual, J. Banchereau, D. Chaussabel, A. O'Garra, An interferoninducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature* 466, 973–
  977 (2010).
- 30. C. I. Bloom, C. M. Graham, M. P. R. Berry, K. A. Wilkinson, T. Oni, F. Rozakeas, Z. Xu, J.
  Rossello-Urgell, D. Chaussabel, J. Banchereau, V. Pascual, M. Lipman, R. J. Wilkinson, A. O'Garra,
  Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis
  Therapy. *PLOS ONE* 7, e46191 (2012).
- 31. T. H. M. Ottenhoff, R. H. Dass, N. Yang, M. M. Zhang, H. E. E. Wong, E. Sahiratmadja, C. C.
  Khor, B. Alisjahbana, R. van Crevel, S. Marzuki, M. Seielstad, E. van de Vosse, M. L. Hibberd,
  Genome-Wide Expression Profiling Identifies Type 1 Interferon Response Pathways in Active
  Tuberculosis. *PLOS ONE* 7, e45839 (2012).
- 32. K. D. Mayer-Barber, B. B. Andrade, D. L. Barber, S. Hieny, C. G. Feng, P. Caspar, S. Oland, S.
  Gordon, A. Sher, Innate and Adaptive Interferons Suppress IL-1α and IL-1β Production by Distinct
  Pulmonary Myeloid Subsets during Mycobacterium tuberculosis Infection. *Immunity* 35, 1023–1034
  (2011).
- 33. K. D. Mayer-Barber, B. B. Andrade, S. D. Oland, E. P. Amaral, D. L. Barber, J. Gonzales, S. C.
  Derrick, R. Shi, N. P. Kumar, W. Wei, X. Yuan, G. Zhang, Y. Cai, S. Babu, M. Catalfamo, A. M.
  Salazar, L. E. Via, C. E. Barry, A. Sher, Host-directed therapy of tuberculosis based on interleukin1 and type I interferon crosstalk. *Nature* **511**, 99–103 (2014).
- 34. D. X. Ji, L. H. Yamashiro, K. J. Chen, N. Mukaida, I. Kramnik, K. H. Darwin, R. E. Vance, Type I
  interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. *Nat. Microbiol.*4, 2128–2135 (2019).

- 35. D. I. Kotov, O. V. Lee, S. A. Fattinger, C. A. Langner, J. V. Guillen, J. M. Peters, A. Moon, E. M.
  Burd, K. C. Witt, D. B. Stetson, D. L. Jaye, B. D. Bryson, R. E. Vance, Early cellular mechanisms of
  type I interferon-driven susceptibility to tuberculosis. *Cell* **186**, 5536-5553.e22 (2023).
- 660 36. L. Moreira-Teixeira, K. Mayer-Barber, A. Sher, A. O'Garra, Type I interferons in tuberculosis: Foe 661 and occasionally friend. *J. Exp. Med.* **215**, 1273–1285 (2018).
- 662 37. I. Kramnik, G. Beamer, Mouse models of human TB pathology: roles in the analysis of necrosis 663 and the development of host-directed therapies. *Semin. Immunopathol.* **38**, 221–237 (2016).
- 38. S. Giosué, M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, G. Pedicelli, L. Rebek, A. Bisetti,
  F. Ameglio, Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. *Am. J. Respir. Crit. Care Med.* **158**, 1156–1162 (1998).
- 39. P. Zarogoulidis, I. Kioumis, N. Papanas, K. Manika, T. Kontakiotis, A. Papagianis, K.
  Zarogoulidis, The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in
  non-responding tuberculosis and diabetes mellitus: a case report and review of the literature. *J. Chemother.* 24, 173–177 (2012).
- 40. D. Mansoori, S. Tavana, M. Mirsaeidi, M. Yazdanpanah, H. Sohrabpour, The Efficacy of
   Interferon-α in the Treatment of Multidrug Resistant Tuberculosis. *TANAFFOS* 1, 29–34 (2002).
- 41. Y. E. Liu, P. A. Darrah, J. J. Zeppa, M. Kamath, F. Laboune, D. C. Douek, P. Maiello, M.
  Roederer, J. L. Flynn, R. A. Seder, P. Khatri, Blood transcriptional correlates of BCG-induced
  protection against tuberculosis in rhesus macaques. *Cell Rep. Med.* 4, 101096 (2023).
- 42. L. B. Tezera, M. K. Bielecka, A. Chancellor, M. T. Reichmann, B. A. Shammari, P. Brace, A.
  Batty, A. Tocheva, S. Jogai, B. G. Marshall, M. Tebruegge, S. N. Jayasinghe, S. Mansour, P. T.
  Elkington, B. Aldridge, Ed. Dissection of the host-pathogen interaction in human tuberculosis using
  a bioengineered 3-dimensional model. *eLife* 6, e21283 (2017).
- 43. V. Torraca, C. Cui, R. Boland, J.-P. Bebelman, A. M. van der Sar, M. J. Smit, M. Siderius, H. P.
  Spaink, A. H. Meijer, The CXCR3-CXCL11 signaling axis mediates macrophage recruitment and
  dissemination of mycobacterial infection. *Dis. Model. Mech.* 8, 253–269 (2015).
- 44. J. M. Davis, H. Clay, J. L. Lewis, N. Ghori, P. Herbomel, L. Ramakrishnan, Real-time visualization
  of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish
  embryos. *Immunity* **17**, 693–702 (2002).
- 45. D. M. Tobin, F. J. Roca, S. F. Oh, R. McFarland, T. W. Vickery, J. P. Ray, D. C. Ko, Y. Zou, N.
  D. Bang, T. T. H. Chau, J. C. Vary, T. R. Hawn, S. J. Dunstan, J. J. Farrar, G. E. Thwaites, M.-C.
  King, C. N. Serhan, L. Ramakrishnan, Host genotype-specific therapies can optimize the
  inflammatory response to mycobacterial infections. *Cell* **148**, 434–446 (2012).
- 690 46. A.-L. Neehus, B. Carey, M. Landekic, P. Panikulam, G. Deutsch, M. Ogishi, C. A. Arango-Franco, 691 Q. Philippot, M. Modaresi, I. Mohammadzadeh, M. Corcini Berndt, D. Rinchai, T. Le Voyer, J. Rosain, 692 M. Momenilandi, M. Martin-Fernandez, T. Khan, J. Bohlen, J. E. Han, A. Deslys, M. Bernard, T. Gajardo-Carrasco, C. Soudée, C. Le Floc'h, M. Migaud, Y. Seeleuthner, M.-S. Jang, E. Nikolouli, S. 693 694 Seyedpour, H. Begueret, J.-F. Emile, P. Le Guen, G. Tavazzi, C. N. J. Colombo, F. C. Marzani, M. 695 Angelini, F. Trespidi, S. Ghirardello, N. Alipour, A. Molitor, R. Carapito, M. Mazloomrezaei, H. Rokni-696 Zadeh, M. Changi-Ashtiani, C. Brouzes, P. Vargas, A. Borghesi, N. Lachmann, S. Bahram, B. 697 Crestani, S. Pahari, L. S. Schlesinger, N. Marr, D. Bugonovic, S. Boisson-Dupuis, V. Béziat, L. Abel, 698 R. Borie, L. R. Young, R. Deterding, M. Shahrooei, N. Rezaei, N. Parvaneh, D. Craven, P. Gros, D. 699 Malo, F. E. Sepulveda, L. M. Nogee, N. Aladjidi, B. C. Trapnell, J.-L. Casanova, J. Bustamante, 700 Human inherited CCR2 deficiency underlies progressive polycystic lung disease. Cell 187, 390-701 408.e23 (2024).
- 47. K. B. Walters, J. M. Green, J. C. Surfus, S. K. Yoo, A. Huttenlocher, Live imaging of neutrophil

- motility in a zebrafish model of WHIM syndrome. *Blood* **116**, 2803–2811 (2010).
- 48. M. H. Lehmann, L. E. Torres-Domínguez, P. J. R. Price, C. Brandmüller, C. J. Kirschning, G.
  Sutter, CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung
  during MVA infection. *J. Leukoc. Biol.* **99**, 1057–1064 (2016).
- 49. M. Buttmann, C. Merzyn, P. Rieckmann, Interferon-beta induces transient systemic IP10/CXCL10 chemokine release in patients with multiple sclerosis. *J. Neuroimmunol.* **156**, 195–203
  (2004).
- 50. C. J. Cambier, K. K. Takaki, R. P. Larson, R. E. Hernandez, D. M. Tobin, K. B. Urdahl, C. L. Cosma, L. Ramakrishnan, Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. *Nature* **505**, 218–222 (2014).
- 51. L. Abel, J. Fellay, D. W. Haas, E. Schurr, G. Srikrishna, M. Urbanowski, N. Chaturvedi, S. Srinivasan, D. H. Johnson, W. R. Bishai, Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. *Lancet Infect. Dis.* **18**, e64–e75 (2018).
- 52. A. Khadela, V. P. Chavda, H. Postwala, Y. Shah, P. Mistry, V. Apostolopoulos, Epigenetics in
   Tuberculosis: Immunomodulation of Host Immune Response. *Vaccines* 10, 1740 (2022).
- 53. A. L. Jacobs, Infective dose in pulmonary tuberculosis. *Tubercle* 22, 266–271 (1941).
- 54. C. R. Plumlee, F. J. Duffy, B. H. Gern, J. L. Delahaye, S. B. Cohen, C. R. Stoltzfus, T. R. Rustad,
  S. G. Hansen, M. K. Axthelm, L. J. Picker, J. D. Aitchison, D. R. Sherman, V. V. Ganusov, M. Y.
  Gerner, D. E. Zak, K. B. Urdahl, Ultra-low Dose Aerosol Infection of Mice with Mycobacterium
  tuberculosis More Closely Models Human Tuberculosis. *Cell Host Microbe* 29, 68-82.e5 (2021).
- 55. J.-L. Casanova, M. S. Anderson, Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs. *J. Clin. Invest.* **133**, e166283.
- 56. P. Elkington, T. Shiomi, R. Breen, R. K. Nuttall, C. A. Ugarte-Gil, N. F. Walker, L. Saraiva, B.
  Pedersen, F. Mauri, M. Lipman, D. R. Edwards, B. D. Robertson, J. D'Armiento, J. S. Friedland,
  MMP-1 drives immunopathology in human tuberculosis and transgenic mice. *J. Clin. Invest.* 121,
  1827–1833 (2011).
- 57. L. Guglielmetti, A. Cazzadori, M. Conti, F. Boccafoglio, A. Vella, R. Ortolani, E. Concia, Lymphocyte subpopulations in active tuberculosis: association with disease severity and the QFT-GIT assay. *Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis.* **17**, 825–828 (2013).
- 58. J. O. Jurado, V. Pasquinelli, I. B. Alvarez, D. Peña, A. I. Rovetta, N. L. Tateosian, H. E. Romeo,
  R. M. Musella, D. Palmero, H. E. Chuluyán, V. E. García, IL-17 and IFN-γ expression in lymphocytes
  from patients with active tuberculosis correlates with the severity of the disease. *J. Leukoc. Biol.* **91**,
  991–1002 (2012).
- 59. Z. Hasan, B. Jamil, J. Khan, R. Ali, M. A. Khan, N. Nasir, M. S. Yusuf, S. Jamil, M. Irfan, R.
  Hussain, Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in
  pulmonary and extrapulmonary tuberculosis is dependent on disease severity. *Scand. J. Immunol.*69, 259–267 (2009).
- 60. J. Roe, C. Venturini, R. K. Gupta, C. Gurry, B. M. Chain, Y. Sun, J. Southern, C. Jackson, M. C.
  Lipman, R. F. Miller, A. R. Martineau, I. Abubakar, M. Noursadeghi, Blood Transcriptomic
  Stratification of Short-term Risk in Contacts of Tuberculosis. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **70**, 731–737 (2020).
- 61. N. L. Bray, H. Pimentel, P. Melsted, L. Pachter, Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).

- 62. C. Soneson, M. I. Love, M. D. Robinson, Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Research* **4**, 1521 (2015).
- 63. S. Durinck, P. T. Spellman, E. Birney, W. Huber, Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).
- 64. J. T. Leek, W. E. Johnson, H. S. Parker, A. E. Jaffe, J. D. Storey, The sva package for removing
  batch effects and other unwanted variation in high-throughput experiments. *Bioinforma. Oxf. Engl.*28, 882–883 (2012).
- 65. H. Fang, B. Knezevic, K. L. Burnham, J. C. Knight, XGR software for enhanced interpretation of
  genomic summary data, illustrated by application to immunological traits. *Genome Med.* 8, 129
  (2016).
- 66. C. T. Turner, J. Brown, E. Shaw, I. Uddin, E. Tsaliki, J. K. Roe, G. Pollara, Y. Sun, J. M. Heather,
  M. Lipman, B. Chain, M. Noursadeghi, Persistent T Cell Repertoire Perturbation and T Cell
  Activation in HIV After Long Term Treatment. *Front. Immunol.* **12**, 634489 (2021).
- 67. M. Jacomy, T. Venturini, S. Heymann, M. Bastian, ForceAtlas2, a continuous graph layout
  algorithm for handy network visualization designed for the Gephi software. *PloS One* 9, e98679
  (2014).
- 68. W. R. Swindell, X. Xing, P. E. Stuart, C. S. Chen, A. Aphale, R. P. Nair, J. J. Voorhees, J. T.
  Elder, A. Johnston, J. E. Gudjonsson, Heterogeneity of inflammatory and cytokine networks in
  chronic plaque psoriasis. *PloS One* 7, e34594 (2012).
- 69. T. Hulsen, J. de Vlieg, W. Alkema, BioVenn a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. *BMC Genomics* **9**, 488 (2008).
- 767 70. C. Nusslein-Volhard, *Zebrafish: A Practical Approach* R. Dahm, Ed. (Oxford University Press, Oxford, 1 edition., 2002).
- 769 71. G. Maarifi, N. Smith, S. Maillet, O. Moncorgé, C. Chamontin, J. Edouard, F. Sohm, F. P. Blanchet,
  770 J.-P. Herbeuval, G. Lutfalla, J.-P. Levraud, N. J. Arhel, S. Nisole, TRIM8 is required for virus-induced
  771 IFN response in human plasmacytoid dendritic cells. *Sci. Adv.* 5, eaax3511 (2019).
- 772 72. K. Voelz, R. L. Gratacap, R. T. Wheeler, A zebrafish larval model reveals early tissue-specific 773 innate immune responses to Mucor circinelloides. *Dis. Model. Mech.* **8**, 1375–1388 (2015).
- 774 73. F. Kroll, G. T. Powell, M. Ghosh, G. Gestri, P. Antinucci, T. J. Hearn, H. Tunbak, S. Lim, H. W.
  775 Dennis, J. M. Fernandez, D. Whitmore, E. Dreosti, S. W. Wilson, E. J. Hoffman, J. Rihel, S. C. Ekker,
  776 D. Y. Stainier, D. Balciunas, Eds. A simple and effective F0 knockout method for rapid screening of
  777 behaviour and other complex phenotypes. *eLife* 10, e59683 (2021).
- 74. D. Aggad, M. Mazel, P. Boudinot, K. E. Mogensen, O. J. Hamming, R. Hartmann, S. Kotenko,
  P. Herbomel, G. Lutfalla, J.-P. Levraud, The two groups of zebrafish virus-induced interferons signal
  via distinct receptors with specific and shared chains. *J. Immunol. Baltim. Md* 1950 183, 3924–3931
  (2009).
- 782 75. K. Takaki, J. M. Davis, K. Winglee, L. Ramakrishnan, Evaluation of the pathogenesis and 783 treatment of Mycobacterium marinum infection in zebrafish. *Nat. Protoc.* **8**, 1114–1124 (2013).
- 784 76. L. M. van Leeuwen, M. van der Kuip, S. A. Youssef, A. de Bruin, W. Bitter, A. M. van Furth, A.
  785 M. van der Sar, Modeling tuberculous meningitis in zebrafish using Mycobacterium marinum. *Dis.*786 *Model. Mech.* 7, 1111–1122 (2014).
- 787 77. E. L. Benard, A. M. van der Sar, F. Ellett, G. J. Lieschke, H. P. Spaink, A. H. Meijer, Infection of 788 zebrafish embryos with intracellular bacterial pathogens. *J. Vis. Exp. JoVE* (2012),

Protective type I interferon responses in mycobacterial infection

- 789 doi:10.3791/3781.
- 790 78. R. N. Wilkinson, S. Elworthy, P. W. Ingham, F. J. M. van Eeden, A method for high-throughput 791 PCR-based genotyping of larval zebrafish tail biopsies. *BioTechniques* **55**, 314–316 (2013).
- 792 79. D. R. Stirling, O. Suleyman, E. Gil, P. M. Elks, V. Torraca, M. Noursadeghi, G. S. Tomlinson, 793 Analysis tools to quantify dissemination of pathology in zebrafish larvae. *Sci. Rep.* **10**, 3149 (2020).
- 80. D. A. Sholl, Dendritic organization in the neurons of the visual and motor cortices of the cat. *J. Anat.* 87, 387–406 (1953).
- 81. S. van der Walt, S. C. Colbert, G. Varoquaux, The NumPy Array: A Structure for Efficient
  Numerical Computation. *Comput. Sci. Eng.* 13, 22–30 (2011).
- 82. S. van der Walt, J. L. Schönberger, J. Nunez-Iglesias, F. Boulogne, J. D. Warner, N. Yager, E.
  Gouillart, T. Yu, scikit-image contributors, scikit-image: image processing in Python. *PeerJ* 2, e453
  (2014).
- 801 83. N. D. Meeker, S. A. Hutchinson, L. Ho, N. S. Trede, Method for isolation of PCR-ready genomic 802 DNA from zebrafish tissues. *BioTechniques* **43**, 610, 612, 614 (2007).
- 803 84. K. Labun, X. Guo, A. Chavez, G. Church, J. A. Gagnon, E. Valen, Accurate analysis of genuine 804 CRISPR editing events with ampliCan. *Genome Res.* **29**, 843–847 (2019).
- 805

# 806 ACKNOWLEDGEMENTS

807 We thank Michelle Berin and Victoria Dean (Clinical Research Nurses, UCL Division of Infection and Immunity) and Mylah Ramirez (Research Nurse, Barts Health NHS Trust) for support with research 808 809 governance, participant recruitment and sample collection. We thank the UCL Zebrafish Facility staff, particularly Heather Callaway, Jenna Hakkesteeg, Karen Dunford, Carole Wilson and Elise 810 811 Hitchcock for maintenance of the zebrafish lines used in this study, especially during the first wave 812 of the COVID-19 pandemic. We thank UCL Genomics for library preparation and sequencing of 813 samples for transcriptional profiling (www.ucl.ac.uk/child-health/research/genetics-and-genomic-814 medicine/ucl-genomics). We thank Alex Lubin and Katie-Jo Miller for next generation sequencing of 815 zebrafish samples for genotyping. This work has benefited from the facilities and expertise of CELPHEDIA-TEFOR, UAR2010 TEFOR Paris-Saclay (TEFOR Infrastructure - Investissement 816 817 d'avenir - ANR-II-INBS-0014) and from the Recombinant Protein Platform of the Institut Pasteur, 818 Paris.

# 819 FUNDING

- 820 UK Medical Research Council Clinician Scientist Fellowship MR/N007727/1 (GST)
- 821 Wellcome Trust Investigator Award 207511/Z/17/Z (MN)
- Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society 105570/Z/14/Z
   (PME)
- 824 Fondation pour la Recherche Medicale grant EQU202203014646 (J-PL)
- National Institute of Health Research Biomedical Research Centre Funding to University College
   Hospitals NHS Foundation Trust and University College London (GST, MN)
- This research was funded in whole, or in part, by the Wellcome Trust [207511/Z/17/Z, 105570/Z/14/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

# 830 AUTHOR CONTRIBUTIONS

- 831 Conceived the study: GST, MN
- 832 Collected the data: ASS, BSMDDE, JR, ET, GP, J-PL, GST

Protective type I interferon responses in mycobacterial infection


- 833 Provided resources or analysis tools: ASS, BSMDDE, JR, CTT, MCIL, HK, GP, PME, EMP, J-PL, 834 MN, GST
- 835 Performed the data analysis / interpretation: ASS, BSMDDE, JR, CTT, GP, PME, EMP, J-PL, MN, 836 GST
- 837 Prepared the manuscript draft: GST, ASS, BSMDDE
- All authors reviewed and contributed to the final manuscript.
- 839 COMPETING INTERESTS
- 840 The authors declare that they have no competing interests.

#### 841 DATA AND MATERIALS AVAILABILITY

842 Human RNAseq data are already available in the ArrayExpress repository under accession number 843 E-MTAB-6816. Zebrafish RNAseq data will be made available in ArrayExpress at the time of peer 844 reviewed publication of the manuscript. The source code and manual for QuantiFish software used 845 for analysis of bacterial burden and dissemination in zebrafish larvae are available at 846 https://github.com/DavidStirling/QuantiFish. The ImageJ macro used to generate montages from the 847 Hermes images and source code and manual for the Python script used for analysis of steady state 848 cell numbers and cellular recruitment zebrafish are available in at 849 https://github.com/AndSzyShe/particle analysis. Source data for figure panels with fewer than 20 850 data points are available in Data file S1.

Protective type I interferon responses in mycobacterial infection

#### 852 FIGURES



854 Fig. 1. Reduced type I interferon activity in the TST transcriptome is associated with 855 increased severity of human TB disease. (A) Frequency distribution of the correlation coefficients for the relationship between the abundance of each of the 3222 transcripts within the tuberculin skin 856 857 test (TST) transcriptome derived from 51 individuals with pulmonary tuberculosis (TB) and 858 radiographic disease severity. Coloured boxes highlight statistically significant correlations (p<0.05). (B, C) Network diagrams of statistically significant (FDR<0.05) cytokines (B) and transcription factors 859 860 (C) predicted to be upstream regulators (red) of target gene modules (blue) whose expression is 861 negatively correlated with radiological TB severity. Size of the nodes for upstream regulators is 862 proportional to -Loq10 p value. Nodes were clustered using the Force Atlas 2 algorithm in Gephi 863 (version 0.9.2). (D, E) The inverse relationship between average expression in each TST sample of 864 two distinct, independently derived gene modules representing type I interferon activity (D) with TB 865 severity (E). r values and p values were derived from two-tailed Spearman rank correlations. CXR = 866 Chest x-ray,  $M\Phi$  = Macrophage, KC = Keratinocyte.

867 868

Protective type I interferon responses in mycobacterial infection







Fig. 2. *M. marinum* infection induces a type I interferon response in zebrafish larvae.
(A) Schematic representation of the human canonical type I interferon signalling pathway (left) which
is highly conserved in zebrafish (right). (B, C) The average expression of two largely non-overlapping
(B) type I interferon inducible gene modules derived from independent data (Table S1) is elevated
in *M. marinum* (Mm) infected embryos (4 days post-intravenous infection) compared with uninfected
(UI) siblings (C). Data are from four independent experiments.

- 877
- 878

Protective type I interferon responses in mycobacterial infection




880

881 Fig. 3. Increased severity of M. marinum infection in stat2 CRISPants. (A) stat2 CRISPant (stat2-/-) and control ribonucleoprotein (RNP) injected (stat2+/+) zebrafish larvae four days post 882 883 intravenous infection with 400 colony forming units (cfu) mCherry-expressing M. marinum. Scale bar 884 = 250 µm. (B) Survival of control and stat2 disrupted zebrafish larvae 1-4 days post infection with 885 M. marinum. p value was derived from a log-rank (Mantel-Cox) test. (C-E) Comparison of integrated 886 fluorescence (IF) (a surrogate for bacterial burden) (C), number of bacterial foci (D) and spatial distribution of bacteria (E), in stat2 CRISPants compared to control RNP injected siblings. Each data 887 point represents an individual zebrafish larva, lines and error bars indicate the median and 888 889 interquartile range. p values were derived from two-tailed Mann-Whitney tests. Data are 890 representative of four experiments.

891

892

Protective type I interferon responses in mycobacterial infection




894

895 Fig. 4. Reduced steady state neutrophil numbers in stat2 CRISPants. (A) Representative images of three day post-fertilisation (dpf) control (upper panel) and stat2 CRISPant (lower panel) 896 897 Tg(mpeg1:mCherry) zebrafish larvae. Scale bar = 250 µm. (B) Integrated fluorescence (IF) as a 898 surrogate for steady state macrophage numbers in three dpf stat2 CRISPants compared to siblings 899 injected with scrambled RNPs. (C) Representative images of two dpf control (upper panel) and stat2 CRISPant (lower panel) Ta(mpx:eGFP) zebrafish larvae. Scale bar = 250 µm. (D) Quantitation of 900 901 baseline neutrophil numbers (represented by IF) in two dpf stat2 CRISPants and negative control 902 RNP injected siblings. Each data point represents an individual zebrafish larva, lines and error bars 903 indicate the median and interguartile range. p values were derived from two-tailed Mann-Whitney 904 tests. Data are from three independent experiments.

905


Protective type I interferon responses in mycobacterial infection



909 Fig. 5. Neutrophil recruitment to the site of sterile injury is not stat2 dependent. 910 (A) Representative images of eGFP-expressing neutrophils recruited to the site of injury 1, 6 and 24 911 hours following tailfin transection of three day post-fertilisation stat2 CRISPant Ta(mpx:eGFP) zebrafish larvae and scrambled RNP injected controls. Scale bar represents 100 µm. (B) Distance 912 of neutrophils from the injury site at 1, 6 and 24 hours post-wound (hpw), derived by identifying the 913 914 Sholl circle in which the maximum integrated fluorescence (IF), a surrogate for highest cell numbers, was detected in stat2 CRISPants and scrambled RNP injected siblings. (C-D) IF, a surrogate for 915 916 total neutrophil numbers (C), and IF at the wound site, representing neutrophil numbers localized to 917 the tailfin transection (D) are shown at 1, 6 and 24 hours following injury. On scatter plots data points represent individual zebrafish larvae and lines and error bars the median and interguartile range. On 918 919 box and whisker plots horizontal lines represent median values, box limits indicate the interguartile 920 range and whiskers extend between the 5th and 95th percentiles. p values were derived from twotailed Mann-Whitney tests. \* = p < 0.05. Data are from three independent experiments. px = Pixels. 921

922

Protective type I interferon responses in mycobacterial infection






924

926 Fig. 6. Reduced macrophage recruitment to the site of sterile injury in stat2 CRISPants. 927 (A) Representative images of mCherry-expressing macrophages recruited to the site of tailfin 928 transection by 6 and 24 hours, in three day post-fertilisation stat2 CRISPant Tg(mpeg1:mCherry) 929 zebrafish embryos and controls. Scale bar represents 100 µm. (B) Comparison of the distance of 930 macrophages from the site of injury at the indicated time points for stat2 CRISPants and control RNP 931 injected siblings. (C) Integrated fluorescence (IF) a surrogate for macrophage numbers at the site of 932 tailfin transection is shown at 1, 6 and 24 hours post-wound (hpw). On scatter plots data points 933 represent individual zebrafish larvae and lines and error bars the median and interguartile range. On box and whisker plots horizontal lines represent median values, box limits indicate the interguartile 934 935 range and whiskers extend between the 5th and 95th percentiles. p values were derived from twotailed Mann-Whitney tests. \* = p<0.05. Data are from three independent experiments. px = Pixels. 936

937

Protective type I interferon responses in mycobacterial infection

939



940

941 Fig. 7. Reduced macrophage and neutrophil recruitment to *M. marinum* in stat2 CRISPants. 942 (A) Representative images of mCherry-expressing macrophages recruited to the hindbrain (dashed 943 white outline) 18 hours following injection of PBS or 200 colony forming units (cfu) M. marinum in two day post-fertilisation (dpf) stat2 CRISPant Tg(mpeg1:mCherry) zebrafish larvae and scrambled 944 ribonucleoprotein (RNP) injected controls. (B) Number of macrophages recruited to the hindbrain in 945 946 response to PBS or *M. marinum* in *stat2* CRISPants and negative control RNP injected siblings. 947 (C) Representative images of eGFP-expressing neutrophils recruited to the hindbrain 6 hours after 948 PBS or *M. marinum* injection (200 cfu) in two dpf stat2 CRISPant and control Tg(mpx:eGFP) 949 zebrafish larvae. (D) Quantitation of neutrophils recruited to the site of *M. marinum* infection in stat2 CRISPants and control siblings. Scale bars represent 100 µm. Data points represent individual 950 951 zebrafish larvae and lines and error bars the median and interquartile range. p values were derived from two-tailed Mann-Whitney tests. \* = p < 0.05. Data are from three independent experiments. 952

953

Protective type I interferon responses in mycobacterial infection

#### 955 TABLES

**Table 1. Clinical and demographic data summary.** Demographic characteristics and magnitude of clinical induration at the site of TST or saline injection are summarised for all study subjects. Duration of anti-tuberculous drug treatment at the time of sampling and radiographic disease severity data are provided for individuals with pulmonary TB. Saline samples were obtained from 17 individuals with pulmonary TB and 32 healthy participants who were people with cured or latent TB, BCG vaccine recipients and healthy volunteers, described previously (8). CXR = chest x-ray. \*Applies only to participants with active TB receiving saline injections.

		TST	Saline
Number		51	49
Age	(median and range)	30 (19-77)	28 (18-75)
Sex	Male	31 (61%)	19 (39%)
	Female	20 (39%)	30 (61%)
Ethnicity	White	21 (41%)	20 (41%)
	Asian	15 (29%)	8 (16%)
	Black	12 (24%)	7 (14%)
	Mixed	2 (4%)	1 (2%)
	South American	1 (2%)	11 (22%)
	Not recorded	NA	2 (4%)
Injection site induration (mm)	(median and range)	20 (0-70)	0
Days TB treatment before TST +/ saline	(median and range)	19 (0-30)	15 (0-28)*
CXR severity score	(median and range)	30 (0-140)	15 (0-110)*